Wikipedia

Talk:Daiichi Sankyo

Latest comment: 10 months ago by Spintendo in topic revised 2023 COI edit requests
Learn more about this page

Removed the erranous food/beverage analogy.

edit
Latest comment: 18 years ago1 comment1 person in discussion

It doesn't belong in an encyclopedia entry for this company Brettgo1 12:51, 22 October 2006 (UTC)Reply

WikiProject class rating

edit
Latest comment: 16 years ago1 comment1 person in discussion

This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class. BetacommandBot 14:54, 9 November 2007 (UTC)Reply

Combination Therapies missing from Product list

edit
Latest comment: 14 years ago1 comment1 person in discussion

Products like Azor and Trivasc (CS-8635) (still pending FDA approval in US) should be be included in the product line up. Perhaps as a sub-bullet of Benicar, as they are derivatives of Benicar.

Also recently, DSI launched in Japan (4/16) Rezaltas (I think this is Trivasc from the description, not sure though). Can someone more knowledgeable confirm this? http://www.daiichisankyo.com/news/2010_04_16_242e2.pdf

Misosoup7 (talk) 21:18, 6 May 2010 (UTC)Reply

Official Pronunciation of Company Name

edit
Latest comment: 5 years ago1 comment1 person in discussion

I made a change in the romanization of the company's name. In normal Japanese, the word for "Ltd" or "Inc" is pronounced "kabushiki-gaisha". However, after research I found that, in company names, the pronunciation "-kaisha" is also common. Regrettably, although I searched web pages in English as well as in Japanese, I was unable to find any info on this matter concerning this particular company. Ceartaigh (talk) 17:31, 29 March 2019 (UTC)Reply

COI edit requests

edit
Latest comment: 3 years ago5 comments2 people in discussion

Hi! I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I'd like to request some updates to this article:

Lead

edit
  • In infobox, adding "Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[1]" under "Key people". (Also, FYI, I previously updated the CEO listed in the infobox with ref, as I figured that would qualify as WP:COIU.)
  • Also in infobox, updating financial figures and number of employees per latest annual report:
|num_employees = 15,348 (as of March 2020)
|revenue = {{profit}} $ 9.028 billion [[US dollar|USD]] ([[Fiscal year|FY]] 2019) (¥ 981.8 billion [[Japanese yen|JPY]]) ([[Fiscal year|FY]] 2019)
|net_income = {{profit}} $ 1.276 billion [[US dollar|USD]] ([[Fiscal year|FY]] 2019) (¥ 138.8 billion [[Japanese yen|JPY]]) ([[Fiscal year|FY]] 2019)[2]
I did the USD/JPY conversion using the average annual exchange rate identified on page 90 of the report: 108.75.
  • Updating "It achieved JPY 2,305.4 billion in revenue in 2018." to "It achieved JPY 981.8 billion in revenue in 2019."
  • In third sentence, adding "American pharmaceutical company American Regent" to the list of subsidiaries, per the first suggested addition to "History" below.

History

edit
  • Adding to first paragraph: In 1990, Sankyo acquired Luitpold-Werk Group, a pharmaceutical company based in Munich.[3] In 2019, Luitpold renamed itself after its American Regent brand.[4] American Regent, now based in the United States, is a subsidiary of Daiichi Sankyo.[5][6]
  • Tweaking the opening of "Kickbacks" from Daiichi Sankyo is being "closely monitored"... to As of 2015, Daiichi Sankyo was being "closely monitored"...
  • In "Kickbacks", after As part of the company's Physician Organization and Discussion program, adding which ran from 2005 through 2011, (per the source cited).
  • Adding after the U3 Pharma mention in "Acquisitions" (or as a new "Recent history" subsection?): Daiichi Sankyo closed U3 Pharma in 2015.[7]
  • Adding to "Acquisitions": The company acquired ramosetron, nicardipine and barnidipine from Astellas Pharma in October 2019.[8]
  • Adding to end of "Acquisitions" (or as a new "Recent history" subsection?):
Daiichi Sankyo transferred 41 of its products in Japan to Alfresa Holdings Corporation for JPY 4.2 billion in 2018 in order to focus on oncology.[9]
In January 2020, the company's market value rose above JPY 5 trillion after the U.S. Food and Drug Administration approval and release of Enhertu,[10] an antibody-drug conjugate for cancer treatment.[11] Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,[10] which agreed in March 2019 to pay up to $6.9 billion to Daiichi Sankyo in exchange for a share of Enhertu's sales.[12][13]

Products

edit

Updating the list accordingly:

  • Merging the two lists, since there are no sources provided for the division (nor is this how the company divides its products)
  • Deleting redundant "win bp piramal" item
  • Deleting, adding, and combining items to reflect the current product list
  • Adding refs for each item, as well as a ref to the comprehensive list on Daiichi's web site
mockup of the edits

Products of Daiichi Sankyo Group

edit
Sankyo Oncology
edit
Daiichi Pharmaceutical Cardiovascular
edit
Daiichi Pharmaceutical Other
edit
clean code for copying

Products

edit
Oncology
edit
Cardiovascular
edit
Other
edit

Pipeline candidates

edit

Updating outdated subsection entirely (tivantinib is no longer in the pipeline, mirogabalin is an approved product (Tarlige), and trials of SUN13837 have been discontinued):

proposed text

Select investigational candidates in Daiichi Sankyo's pipeline include:

Thank you for your time and your feedback! Mary Gaulke (talk) 18:09, 20 May 2021 (UTC)Reply

@MaryGaulke: I'll look at this tomorrow when I have more time. ···日本穣 · 投稿 · Talk to Nihonjoe · Join WP Japan! 23:39, 14 June 2021 (UTC)Reply
Updated through the products list. Note that Wikipedia is not for listing every product for every company. I've left the list as is and added a reference link to the company product list. ···日本穣 · 投稿 · Talk to Nihonjoe · Join WP Japan! 17:38, 15 June 2021 (UTC)Reply
Okay, I think I've gotten all of them. ···日本穣 · 投稿 · Talk to Nihonjoe · Join WP Japan! 17:55, 15 June 2021 (UTC)Reply
Thanks so much for your help! Mary Gaulke (talk) 13:50, 16 June 2021 (UTC)Reply

References

  1. ^ "Corporate Management Information – Ken Keller". Daiichi Sankyo, Inc. Retrieved 30 November 2020.
  2. ^ "Value Report 2020" (PDF). Daiichi Sankyo Group. 31 March 2020. p. 45. Retrieved 30 November 2020.
  3. ^ "Sankyo Buys Drug Maker". The New York Times. 19 January 1990. Retrieved 17 December 2020.
  4. ^ "Luitpold Pharmaceuticals Renamed American Regent". American Pharmaceutical Review. 2 January 2019. Retrieved 17 December 2020.
  5. ^ "Daiichi Sankyo creates new biz unit for oncology". BioSpectrum Asia. 13 November 2020. Retrieved 17 December 2020.
  6. ^ "Leadership Transitions Upcoming at Daiichi Sankyo, American Regent". PharmaLive. 7 December 2020. Retrieved 17 December 2020.
  7. ^ White, Victoria (1 December 2015). "Daiichi Sankyo to close research subsidiary U3 Pharma". Drug Target Review. Retrieved 1 December 2020.
  8. ^ "Daiichi Sankyo buys three drugs to boost presence in Asia". The Pharma Letter. 15 October 2019. Retrieved 1 December 2020.
  9. ^ "Daiichi Sankyo splits to offload old assets and focus on oncology ambition". The Pharma Letter. 1 August 2018. Retrieved 1 December 2020.
  10. ^ a b Takada, Noriyuki; Kawana, Yukihiro; Sakabe, Yoshinaru (28 January 2020). "Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold". Nikkei Asia. Retrieved 1 December 2020.
  11. ^ Matsuyama, Kanoko (16 June 2019). "Drug devised to replace chemotherapy may reshape cancer care". The Japan Times. Retrieved 1 December 2020.
  12. ^ Terry, Mark (29 March 2019). "AstraZeneca and Daiichi Sankyo Sign $6.9 Billion Deal for a Single Cancer Drug". BioSpace. Retrieved 1 December 2020.
  13. ^ Tatelbaum, Julianna (29 March 2019). "Global pharma giant AstraZeneca strikes $6.9 billion deal to expand cancer portfolio". CNBC. Retrieved 1 December 2020.
  14. ^ "AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu". PMLive. 23 December 2019. Retrieved 3 December 2020.
  15. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  16. ^ "FDA approves Turalio, the first therapy for rare joint tumor". The Pharma Letter. 3 August 2019. Retrieved 3 December 2020.
  17. ^ Idrus, Amirah Al (21 June 2019). "FDA nixes Daiichi's blood cancer drug quizartinib after Japanese regulators wave it through". Fierce Biotech. Retrieved 3 December 2020.
  18. ^ Weinberg, Ido (9 January 2015). "FDA approves edoxaban to reduce stroke risk, treat DVT and PE". Healio. Retrieved 3 December 2020.
  19. ^ "FDA approves Daiichi Sankyo bloodthinner Savaysa". PharmaTimes. 9 January 2015. Retrieved 3 December 2020.
  20. ^ Terry, Mark (8 November 2019). "Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial". BioSpace. Retrieved 3 December 2020.
  21. ^ Elvidge, Suzanne (2 August 2017). "Daiichi spends $300M to settle Benicar suits". BioPharma Dive. Retrieved 3 December 2020.
  22. ^ "Daiichi Sankyo says prasugrel hits goals in thrombotic stroke study". The Pharma Letter. 21 July 2020. Retrieved 3 December 2020.
  23. ^ "EC nod for Daiichi Sankyo's cholesterol lowerers Nilemdo and Nustendi". The Pharma Letter. 6 April 2020. Retrieved 13 May 2021.
  24. ^ "New combination therapy for type 2 diabetes approved in Japan". The Pharma Letter. 3 July 2017. Retrieved 3 December 2020.
  25. ^ Dey, Sushmi (9 October 2012). "Ranbaxy launches authorised generic of Daiichi's Evoxac in US". Business Standard India. Retrieved 13 May 2021.
  26. ^ Steinberg, Julie (29 July 2020). "Daiichi Sankyo Still Faces Claims Over Injectable Anemia Drug". Bloomberg Law. Retrieved 3 December 2020.
  27. ^ "Daiichi Sankyo Looking to Establish "Base Treatment" Position for Memary". Pharma Japan. 23 April 2012. Retrieved 3 December 2020.
  28. ^ "AZ pockets $100 million in Daiichi Sankyo deal for Nexium". PharmaTimes. 29 October 2010. Retrieved 3 December 2020.
  29. ^ "Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan". The Pharma Letter. 29 August 2013. Retrieved 3 December 2020.
  30. ^ "Daiichi Sankyo debuts bone cancer drug Ranmark in Japan". The Pharma Letter. 17 April 2012. Retrieved 3 December 2020.
  31. ^ "Daiichi Sankyo wins approval to compete with Lyrica in Japan". The Pharma Letter. 9 January 2019. Retrieved 3 December 2020.
  32. ^ Haneda, Masakazu; Kadowaki, Takashi; Ito, Hiroshi; Sasaki, Kazuyo; Hiraide, Sonoe; Ishii, Manabu; Matsukawa, Miyuki; Ueno, Makoto (2018). "Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance". Diabetes Therapy. 9 (3): 1083–1097. doi:10.1007/s13300-018-0416-2. PMC 5984919. PMID 29637459.
  33. ^ Bulik, Beth Snyder (1 April 2018). "Daiichi Sankyo partners with Crohn's & Colitis Foundation to draw attention to iron deficiency". Fierce Pharma. Retrieved 3 December 2020.
  34. ^ "UCB and Daiichi Sankyo's Vimpat approved in Japan". The Pharma Letter. 4 July 2016. Retrieved 3 December 2020.
  35. ^ "Daiichi Sankyo says FDA OKs Welchol for diabetes treatment". Reuters. 18 January 2008. Retrieved 3 December 2020.
  36. ^ "First-in-class skin cancer drug approved". PMLive. 18 August 2011. Retrieved 13 May 2021.
  37. ^ "Products". Daiichi Sankyo. Retrieved 2 December 2020.
  38. ^ "AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu". PMLive. 23 December 2019. Retrieved 3 December 2020.
  39. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  40. ^ "FDA approves Turalio, the first therapy for rare joint tumor". The Pharma Letter. 3 August 2019. Retrieved 3 December 2020.
  41. ^ Idrus, Amirah Al (21 June 2019). "FDA nixes Daiichi's blood cancer drug quizartinib after Japanese regulators wave it through". Fierce Biotech. Retrieved 3 December 2020.
  42. ^ Weinberg, Ido (9 January 2015). "FDA approves edoxaban to reduce stroke risk, treat DVT and PE". Healio. Retrieved 3 December 2020.
  43. ^ "FDA approves Daiichi Sankyo bloodthinner Savaysa". PharmaTimes. 9 January 2015. Retrieved 3 December 2020.
  44. ^ Terry, Mark (8 November 2019). "Daiichi Sankyo's Hypertension Drug Hits Mark in Diabetic Nephropathy Trial". BioSpace. Retrieved 3 December 2020.
  45. ^ Elvidge, Suzanne (2 August 2017). "Daiichi spends $300M to settle Benicar suits". BioPharma Dive. Retrieved 3 December 2020.
  46. ^ "Daiichi Sankyo says prasugrel hits goals in thrombotic stroke study". The Pharma Letter. 21 July 2020. Retrieved 3 December 2020.
  47. ^ "EC nod for Daiichi Sankyo's cholesterol lowerers Nilemdo and Nustendi". The Pharma Letter. 6 April 2020. Retrieved 13 May 2021.
  48. ^ "New combination therapy for type 2 diabetes approved in Japan". The Pharma Letter. 3 July 2017. Retrieved 3 December 2020.
  49. ^ Dey, Sushmi (9 October 2012). "Ranbaxy launches authorised generic of Daiichi's Evoxac in US". Business Standard India. Retrieved 13 May 2021.
  50. ^ Steinberg, Julie (29 July 2020). "Daiichi Sankyo Still Faces Claims Over Injectable Anemia Drug". Bloomberg Law. Retrieved 3 December 2020.
  51. ^ "Daiichi Sankyo Looking to Establish "Base Treatment" Position for Memary". Pharma Japan. 23 April 2012. Retrieved 3 December 2020.
  52. ^ "AZ pockets $100 million in Daiichi Sankyo deal for Nexium". PharmaTimes. 29 October 2010. Retrieved 3 December 2020.
  53. ^ "Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan". The Pharma Letter. 29 August 2013. Retrieved 3 December 2020.
  54. ^ "Daiichi Sankyo debuts bone cancer drug Ranmark in Japan". The Pharma Letter. 17 April 2012. Retrieved 3 December 2020.
  55. ^ "Daiichi Sankyo wins approval to compete with Lyrica in Japan". The Pharma Letter. 9 January 2019. Retrieved 3 December 2020.
  56. ^ Haneda, Masakazu; Kadowaki, Takashi; Ito, Hiroshi; Sasaki, Kazuyo; Hiraide, Sonoe; Ishii, Manabu; Matsukawa, Miyuki; Ueno, Makoto (2018). "Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance". Diabetes Therapy. 9 (3): 1083–1097. doi:10.1007/s13300-018-0416-2. PMC 5984919. PMID 29637459.
  57. ^ Bulik, Beth Snyder (1 April 2018). "Daiichi Sankyo partners with Crohn's & Colitis Foundation to draw attention to iron deficiency". Fierce Pharma. Retrieved 3 December 2020.
  58. ^ "UCB and Daiichi Sankyo's Vimpat approved in Japan". The Pharma Letter. 4 July 2016. Retrieved 3 December 2020.
  59. ^ "Daiichi Sankyo says FDA OKs Welchol for diabetes treatment". Reuters. 18 January 2008. Retrieved 3 December 2020.
  60. ^ "First-in-class skin cancer drug approved". PMLive. 18 August 2011. Retrieved 13 May 2021.
  61. ^ "Products". Daiichi Sankyo. Retrieved 2 December 2020.
  62. ^ "Datopotamab deruxtecan – DS-1062 (TROP2 ADC)". ADC Review. Retrieved 17 December 2020.
  63. ^ Hergert, Jessica (31 January 2021). "Relapsed/Refractory Metastatic NSCLC Tumors Respond to Datopotamab Deruxtecan in Early Trial". Cancer Network. Retrieved 13 May 2021.
  64. ^ "Patritumab Deruxtecan – U3-1402 – HER3 ADC". ADC Review. Retrieved 17 December 2020.
  65. ^ Seymour, Caroline (30 January 2021). "Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC". Targeted Oncology. Retrieved 13 May 2021.
  66. ^ "Daiichi Sankyo sets out plans for dissolution of Japan Vaccine". The Pharma Letter. 26 December 2018. Retrieved 3 December 2020.
  67. ^ "Daiichi Sankyo sets up collaborations for valemetostat in B-cell lymph". The Pharma Letter. 25 February 2021. Retrieved 13 May 2021.
  68. ^ "Daiichi Sankyo's Oncolytic Virus Gets Orphan Status". Pharma Japan. 12 July 2017. Retrieved 17 December 2020.

2023 COI edit requests

edit
Latest comment: 1 year ago2 comments2 people in discussion

Hi! As noted above, I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I have some new requests for this article:

Lead
  • In the infobox, update
|key_people =
  • Sunao Manabe (Representative Director, and President)[1][2]
  • Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[3]
|num_employees = 15,348 (as of March 2020)
to
|key_people =
  • Sunao Manabe (Representative Director and CEO)
  • Hiroyuki Okuzawa (Representative Director, President and COO)[4]
  • Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
  • Ken Takeshita, MD (Global Research & Development Chief, Daiichi Sankyo, Inc.)[5]
|num_employees = 17,435 (as of May 2023)[6]
  • In the infobox, update
|revenue =   $ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019)
|net_income =   $ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019)
to
|revenue =   $ 9.44 billion USD (FY 2022) (¥ 1,278 billion JPY) (FY 2022)
|net_income =   $ 812 million USD (FY 2022) (¥ 109.2 billion JPY) (FY 2022)[7]
  • Update
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8][9] and it seems odd to me to include the former Ranbaxy ownership in the lead.
  • Update
Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan),[10] a HER2 directed antibody-drug conjugate (ADC)[11] and the lead ADC in the company's oncology portfolio.[12]
Daiichi Sankyo's patent on Benicar expired several years ago;[13][14] Cosette Pharmaceuticals now holds US sales and distribution rights.[15] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[16][10]
Acquisitions
  • Move
The shutdown of Plexxikon was announced in 2022[17] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[18]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
  • Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
  • In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib.[19]", delete "Phase III" – quizartinib is now approved for use in Japan[20] and in the United States.[21]
  • Update
Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,[22]
to
Enhertu has been patented by Daiichi Sankyo[23] and is being co-developed and co-commercialized in cooperation with AstraZeneca,[22]
Products
Oncology
  • Add:
  • Update
to
Cardiovascular

Delete

Since Daiichi Sankyo no longer holds the rights to Benicar.[15]

Pipeline candidates
  • Delete
Since it's now an oncology product, noted above.
  • Add
  • DS-1211[31]
  • DS-5670 (Japan only)[32]
  • Ifinatamab deruxtecan (I-DXd; DS-7300)[33]
  • Raludotatug deruxtecan (R-DXd; DS-6000)[34][35]


Sources

  1. ^ "Daiichi Sankyo name current COO Sunao Manabe as firm's new CEO". Pharmafile. 4 December 2019. Retrieved 12 November 2020.
  2. ^ "Message from Our CEO". Daiichi Sankyo. Retrieved 12 November 2020.
  3. ^ "Corporate Management Information – Ken Keller". Daiichi Sankyo, Inc. Retrieved 30 November 2020.
  4. ^ "Our Leadership - Our Mission & Strengths - About Us". Daiichi Sankyo. Retrieved 13 April 2023.
  5. ^ "Corporate Management Information". Daiichi Sankyo US. Retrieved 13 April 2023.
  6. ^ "About Us". Daiichi Sankyo. Retrieved 15 May 2023.
  7. ^ a b "Consolidated Financial Results for Year Ended March 31, 2023 (Fiscal 2022)" (PDF). Daiichi Sankyo. 27 April 2023. Retrieved 18 May 2023.
  8. ^ Terry, Mark (12 January 2022). "Daiichi Sankyo Shuttering Plexxikon Site in Favor of ADCs". BioSpace. Retrieved 12 April 2023.
  9. ^ Cite error: The named reference Leuty was invoked but never defined (see the help page).
  10. ^ a b Kuchler, Hannah (6 January 2023). "A pharma partnership that brought a breakthrough in breast cancer". Financial Times. Retrieved 13 April 2023.
  11. ^ Becker, Zoey (12 August 2022). "AZ, Daiichi Sankyo's Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer". Fierce Pharma. Retrieved 13 April 2023.
  12. ^ GlobalData Healthcare (16 August 2022). "More big wins for the AstraZeneca-Daiichi Sankyo collaboration". Pharmaceutical Technology. Retrieved 13 April 2023.
  13. ^ Haydock, Ian (19 October 2015). "Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry". Pharma Intelligence. Retrieved 13 April 2023.
  14. ^ Macdonald, Gareth (5 April 2016). "Daiichi Sankyo: looming Benicar patent loss and large molecule focus prompted plant closure". Outsourcing-Pharma. Retrieved 13 April 2023.
  15. ^ a b Ghumatkar, Pranav (18 January 2022). "Cosette Pharmaceuticals acquires rights to eight branded products from Daiichi Sankyo". Seeking Alpha. Retrieved 13 April 2023.
  16. ^ Snyder Bulik, Beth (23 November 2020). "Daiichi Sankyo takes oncology shift into next phase with new global business unit". Fierce Pharma. Retrieved 13 April 2023.
  17. ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.
  18. ^ Taylor, Nick P. (2022-01-12). "Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development". Fierce Biotech. Archived from the original on 2022-01-12.
  19. ^ "GEN - News Highlights:Daiichi Sankyo to Acquire Ambit Biosciences for Up to $410M". GEN. 2014-09-29.
  20. ^ "Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML" (Press release). Retrieved 16 February 2021.
  21. ^ "FDA approves quizartinib for newly diagnosed acute myeloid leukemia". U.S. Food and Drug Administration (FDA). 20 July 2023. Archived from the original on 21 July 2023. Retrieved 21 July 2023.
  22. ^ a b Takada, Noriyuki; Kawana, Yukihiro; Sakabe, Yoshinaru (28 January 2020). "Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold". Nikkei Asia. Retrieved 1 December 2020.
  23. ^ Taylor, Phil (17 February 2023). "Daiichi Sankyo wins round in Enhertu patent dispute". Pharmaphorum. Retrieved 19 September 2023.
  24. ^ "Dual EZH1 and EZH2 inhibitor Ezharmia launched in Japan". The Pharma Letter. 20 December 2022. Retrieved 13 April 2023.
  25. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  26. ^ "FDA approves Turalio, the first therapy for rare joint tumor". The Pharma Letter. 3 August 2019. Retrieved 3 December 2020.
  27. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  28. ^ "FDA approves Turalio, the first therapy for rare joint tumor". The Pharma Letter. 3 August 2019. Retrieved 3 December 2020.
  29. ^ Elvidge, Suzanne (2 August 2017). "Daiichi spends $300M to settle Benicar suits". BioPharma Dive. Retrieved 3 December 2020.
  30. ^ "Daiichi Sankyo sets up collaborations for valemetostat in B-cell lymph". The Pharma Letter. 25 February 2021. Retrieved 13 May 2021.
  31. ^ "Daiichi Sankyo, SBP begin phase 1 trial of DS-1211 in hyealthy volunteers". PharmaBiz. 11 September 2017. Retrieved 13 April 2023.
  32. ^ "Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine". Reuters. 13 January 2023. Retrieved 13 April 2023.
  33. ^ "Daiichi Sankyo submits Enhertu sNDA to Japan to treat patients with HER2 mutant metastatic non-small cell lung cancer". PharmaBiz. 14 December 2022. Retrieved 13 April 2023.
  34. ^ Suzuki, H.; Nagase, S.; Saito, C.; Nagata, M.; Kaneda, Y.; Honda, K.; Nishiya, Y.; Honda, T.; Nakada, T.; Goto, R.; Ishizaka, T.; Myobatake, Y.; Abe, Y.; Agatsuma, T. (2021). "10P DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXD, demonstrates potent antitumor activity in preclinical models". Annals of Oncology. 32: S363–S364. doi:10.1016/j.annonc.2021.08.288. S2CID 239102242.
  35. ^ "Raludotatug deruxtecan - Daiichi Sankyo". AdisInsight. 11 November 2022. Retrieved 23 June 2023.

Thank you for your time! Mary Gaulke (talk) 21:14, 19 October 2023 (UTC)Reply

I'm sorry, but this request needs a quick go-over before it's ready for review. There are several instances where two references are verifying the same information, which need to be consolidated into one reference. I'd also like to see Wikilinks for any |key people= who are not president, chairman or CEO (Wikilinks for Pipeline candidates as well) There is also the proposed text where we learn that Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca and then, later on in the text, we again discover that Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan) Why are both of these passages of text being asked to be placed/re-placed into the article? Lastly, while on the subject of Enhertu, there is a HER2 directed antibody-drug conjugate (ADC) and the lead ADC in the company's oncology portfolio which is problematic, as the phrase "lead drug in their portfolio" sounds like something ripped from the company's website, which we can do without. Thank you in advance for these changes! Regards,  Spintendo  01:20, 20 October 2023 (UTC)Reply

revised 2023 COI edit requests

edit
Latest comment: 10 months ago2 comments2 people in discussion

Hi again – I've revised the edit requests below in response to the feedback above.

Lead
  • In the infobox, update
|key_people =
  • Sunao Manabe (Representative Director, and President)[1][2]
  • Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[3]
|num_employees = 15,348 (as of March 2020)
to
|key_people =
  • Sunao Manabe (Representative Director and CEO)
  • Hiroyuki Okuzawa (Representative Director, President and COO)[4]
  • Ken Keller (President and CEO, Daiichi Sankyo, Inc.)[5]
|num_employees = 17,435 (as of May 2023)[6]
  • In the infobox, update
|revenue =   $ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019)
|net_income =   $ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019)
to
|revenue =   $ 9.44 billion USD (FY 2022) (¥ 1,278 billion JPY) (FY 2022)
|net_income =   $ 812 million USD (FY 2022) (¥ 109.2 billion JPY) (FY 2022)[7]
  • Update
It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India.
to
It achieved JPY 1,278 billion in revenue in 2022.[7] The company owns the American pharmaceutical company American Regent.
Plexxikon has been closed,[8] and it seems odd to me to include the former Ranbaxy ownership in the lead.
  • Update
Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
to
Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan),[9] a HER2 directed antibody-drug conjugate (ADC)[10] and the primary ADC in the company's oncology portfolio.[11]
Daiichi Sankyo's patent on Benicar expired several years ago;[12] Cosette Pharmaceuticals now holds US sales and distribution rights.[13] I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.[14]
Acquisitions
  • Move
The shutdown of Plexxikon was announced in 2022[15] as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.[16]
from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).
  • Delete
The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
This sentence is outdated and superseded by subsequent information.
  • In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib.[17]", delete "Phase III" – quizartinib is now approved for use in Japan[18] and in the United States.[19]
  • Update
Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,[20]
to
Enhertu has been patented by Daiichi Sankyo[21] and is being co-developed and co-commercialized in cooperation with AstraZeneca,[20]
Per Spintendo's feedback above, noting I'm proposing Enhertu-related text for both the lead and Acquisitions section per MOS:LEADNOTUNIQUE, specifically the guideline that the information in the lead should generally also appear in the body of the article.
Products
Oncology
  • Add:
  • Update
to
Cardiovascular

Delete

Since Daiichi Sankyo no longer holds the rights to Benicar.[13]

Pipeline candidates
  • Delete
Since it's now an oncology product, noted above.
  • Add


Sources

  1. ^ "Daiichi Sankyo name current COO Sunao Manabe as firm's new CEO". Pharmafile. 4 December 2019. Retrieved 12 November 2020.
  2. ^ "Message from Our CEO". Daiichi Sankyo. Retrieved 12 November 2020.
  3. ^ "Corporate Management Information – Ken Keller". Daiichi Sankyo, Inc. Retrieved 30 November 2020.
  4. ^ "Our Leadership - Our Mission & Strengths - About Us". Daiichi Sankyo. Retrieved 13 April 2023.
  5. ^ "Corporate Management Information". Daiichi Sankyo US. Retrieved 13 April 2023.
  6. ^ "About Us". Daiichi Sankyo. Retrieved 15 May 2023.
  7. ^ a b "Consolidated Financial Results for Year Ended March 31, 2023 (Fiscal 2022)" (PDF). Daiichi Sankyo. 27 April 2023. Retrieved 18 May 2023.
  8. ^ Terry, Mark (12 January 2022). "Daiichi Sankyo Shuttering Plexxikon Site in Favor of ADCs". BioSpace. Retrieved 12 April 2023.
  9. ^ Kuchler, Hannah (6 January 2023). "A pharma partnership that brought a breakthrough in breast cancer". Financial Times. Retrieved 13 April 2023.
  10. ^ Becker, Zoey (12 August 2022). "AZ, Daiichi Sankyo's Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer". Fierce Pharma. Retrieved 13 April 2023.
  11. ^ GlobalData Healthcare (16 August 2022). "More big wins for the AstraZeneca-Daiichi Sankyo collaboration". Pharmaceutical Technology. Retrieved 13 April 2023.
  12. ^ Haydock, Ian (19 October 2015). "Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry". Pharma Intelligence. Retrieved 13 April 2023.
  13. ^ a b Ghumatkar, Pranav (18 January 2022). "Cosette Pharmaceuticals acquires rights to eight branded products from Daiichi Sankyo". Seeking Alpha. Retrieved 13 April 2023.
  14. ^ Snyder Bulik, Beth (23 November 2020). "Daiichi Sankyo takes oncology shift into next phase with new global business unit". Fierce Pharma. Retrieved 13 April 2023.
  15. ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.
  16. ^ Taylor, Nick P. (2022-01-12). "Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development". Fierce Biotech. Archived from the original on 2022-01-12.
  17. ^ "GEN - News Highlights:Daiichi Sankyo to Acquire Ambit Biosciences for Up to $410M". GEN. 2014-09-29.
  18. ^ "Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML" (Press release). Retrieved 16 February 2021.
  19. ^ "FDA approves quizartinib for newly diagnosed acute myeloid leukemia". U.S. Food and Drug Administration (FDA). 20 July 2023. Archived from the original on 21 July 2023. Retrieved 21 July 2023.
  20. ^ a b Takada, Noriyuki; Kawana, Yukihiro; Sakabe, Yoshinaru (28 January 2020). "Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold". Nikkei Asia. Retrieved 1 December 2020.
  21. ^ Taylor, Phil (17 February 2023). "Daiichi Sankyo wins round in Enhertu patent dispute". Pharmaphorum. Retrieved 19 September 2023.
  22. ^ "Dual EZH1 and EZH2 inhibitor Ezharmia launched in Japan". The Pharma Letter. 20 December 2022. Retrieved 13 April 2023.
  23. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  24. ^ "FDA approves Turalio, the first therapy for rare joint tumor". The Pharma Letter. 3 August 2019. Retrieved 3 December 2020.
  25. ^ Taylor, Phil (5 August 2019). "Daiichi Sankyo's pexidartinib is first FDA-approved drug for rare tumour". Pharma Phorum. Retrieved 3 December 2020.
  26. ^ Elvidge, Suzanne (2 August 2017). "Daiichi spends $300M to settle Benicar suits". BioPharma Dive. Retrieved 3 December 2020.
  27. ^ "Daiichi Sankyo sets up collaborations for valemetostat in B-cell lymph". The Pharma Letter. 25 February 2021. Retrieved 13 May 2021.
  28. ^ "Daiichi Sankyo submits Enhertu sNDA to Japan to treat patients with HER2 mutant metastatic non-small cell lung cancer". PharmaBiz. 14 December 2022. Retrieved 13 April 2023.

Please let me know if there's any other feedback. Thank you for your time! Mary Gaulke (talk) 13:31, 4 December 2023 (UTC)Reply

  Approved The proposed Enhertu lead section was not included. The claim regarding Enhertu being "co-developed and co-commercialized" with AZ was not updated because the current wording is sufficient while the term "co-commercialized" may not be one that is easily recognized nor relevant to readers (that is, the fact that they're splitting the cost of advertising may not be relevant to all readers). Regards,  Spintendo  05:20, 25 December 2023 (UTC)Reply
Add topic
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Daiichi_Sankyo&oldid=1206863802"